Reported Antitumor Activity of MDV3100 in a Phase 1-2 Study of Advanced Prostate Cancer – A Great Success
Updated: 2010-05-31 17:07:42
At the on-going AUA Meeting, Dr. Howard Scher along with a collaborating group of medical oncologists reported their data from a Phase I-II trial of MDV3100 in castration-resistant prostate cancer (CRPC).
MDV3100 is an oral androgen receptor (AR) antagonist (androgen blocker). Their findings show that it binds to the androgen receptors (AR) on the surface [...]